In clinical observational studies that reported the use of eculizumab in HELLP syndrome, inhibition of C5 resulted in a reduction of hemolysis, a decrease of liver enzyme levels, a decrease in sFlt‐1, an increase in VEGF, and reduced tissular deposition of C5b‐9 complexes in villous trophoblast cells (Burwick and Feinberg 2013). The gene discussed is C5; the disease is HELLP syndrome.